Introduction: Patients with polymyositis and dermatomyositis (PM/DM) are prone to multiple complications that may lead to increased mortality rates. Data about PM/DM mortality in Mexico are lacking.
Objective: The aim of this study was to assess mortality trends in PM/DM in Mexico across 2 decades (2000-2019), overall, by sex, age group, and geographic region.
Methods: From 2000 to 2019, PM/DM deaths were identified in Mexican open-access health databases using the International Classification of Diseases, 10th Revision. Age-standardized mortality rates (ASMRs) per 100,000 inhabitants were calculated for PM/DM and non-PM/DM deaths by sex and geographic region. The annual percent change (APC) in ASMR was calculated using Joinpoint Regression Software.
Results: We found 11.3 million non-PM/DM deaths and 1456 PM/DM deaths in Mexico during the period 2000-2019. Seventy percent of PM/DM deaths occurred in females. PM/DM ASMR was 0.06-0.07/100,000 inhabitants and higher in females (0.08-0.11/100,000). Remarkably, 40% of PM/DM deaths happened in individuals younger than 45 years. This was almost double the percentage than in non-PM/DM deaths. A significant PM/DM ASMR downtrend was identified from 2007 to 2017 (APC, -3.2%; 95% confidence interval, -5.3 to -1.0; p = 0.008), whereas mortality trends were stable for non-PM/DM deaths. No significant changes through time were identified in PM/DM mortality by geographic region in Mexico; however, an increment in PM/DM to non-PM/DM ASMR ratio was detected in the north (+17.6%) and southeast (+84.9%) of Mexico.
Conclusions: Mexico's PM/DM mortality rates have significantly decreased over the past 2 decades, particularly from 2007 to 2017. This trend is more pronounced among younger individuals and those outside the country's southeastern region.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RHU.0000000000002211 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-Based Study From 2000 to 2019.
J Clin Rheumatol
March 2025
Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social, Puebla, Mexico.
Introduction: Patients with polymyositis and dermatomyositis (PM/DM) are prone to multiple complications that may lead to increased mortality rates. Data about PM/DM mortality in Mexico are lacking.
Objective: The aim of this study was to assess mortality trends in PM/DM in Mexico across 2 decades (2000-2019), overall, by sex, age group, and geographic region.
Risk of atherosclerosis-related diseases in polymyositis and dermatomyositis patients: A large-scale population-based study.
Atherosclerosis
February 2025
Rehabilitation Division, Sheba Medical Center, Tel-Hashomer, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Background And Aims: Several systemic autoimmune diseases predispose to the enhancement of Atherosclerotic Cardiovascular Disease (ASCVD). These findings underline the role of inflammation in atherogenesis. Dermatomyositis (DM) and polymyositis (PM) are polygenic autoimmune disorders involving mainly skeletal muscles.
View Article and Find Full Text PDFAutoantibodies in systemic sclerosis overlap syndrome and their correlation with organ damage and survival.
Ann Med
December 2024
Department of Rheumatology and Immunology, Peking University People's Hospital & Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China.
Article Synopsis
- Systemic sclerosis (SSc) can happen alongside other autoimmune diseases, creating a mix called SSc overlap syndrome (SSc OS). Scientists looked at how certain antibodies in the blood relate to the disease and patients' health.
- In a study with 141 patients, they found that the most common antibody was anti-Ro-52, relating it to different organ damages and health issues in SSc OS.
- They discovered that problems like kidney crises and high blood pressure in the lungs are serious risks that can affect survival for these patients.
Serum ferritin as a significant biomarker for patients with idiopathic inflammatory myopathy-associated interstitial lung disease: A systematic review and meta-analysis.
Semin Arthritis Rheum
February 2024
Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Electronic address:
Objective: The biomarkers for predicting the occurrence, progression, and death of idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) remain unclear. Serum ferritin (SF) is a potential candidate and this systematic review and meta-analysis aimed to reveal the clinical significance of SF in IIM-ILD.
Methods: Eligible English studies were selected from PubMed, Embase, Web of science and Scopus up to 9 June 2023.
Paraneoplastic dermatomyositis associated with urothelial cancer: report of a case and systematic review of the literature.
Front Oncol
October 2023
Oncology Department, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Girona, Spain.
Background: The idiopathic inflammatory myopathies (IIM) are a collection of autoimmune diseases that have a substantial impact on the entire body and include conditions such as dermatomyositis (DM), polymyositis (PM), sporadic inclusion body myositis, and immune-mediated necrotizing myopathy. These disorders are characterized by symptoms such as muscular weakness, pain, and dermal rash. This systematic review is intended to explore the potential link between bladder cancer and DM/PM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!